<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753036</url>
  </required_header>
  <id_info>
    <org_study_id>EA4/069/14</org_study_id>
    <nct_id>NCT02753036</nct_id>
  </id_info>
  <brief_title>Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer</brief_title>
  <acronym>CICARO</acronym>
  <official_title>Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer (CICARO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurotoxic phenomena are among the most common and difficult to treat side effects of
      chemotherapy. The development of chemotherapy induced peripheral neuropathy (CIPN) is a
      well-recognized adverse reaction in the peripheral nervous system. Side effects of
      chemotherapy in the central nervous system, however, particularly changes of cognitive
      function (in non-medical literature referred to as &quot;chemobrain&quot;) are diffuse and difficult to
      attribute to individual cytostatic drugs. The primary purpose of this study is to assess
      cognitive function in patients with ovarian and breast cancer before and after systemic
      chemotherapy with paclitaxel with standardized neuropsychological tests and compare the
      outcome to patients with benign gynecological tumors and breast cancer without chemotherapy
      treatment, respectively. Secondary parameters include the assessment of olfactory function,
      total neuropathy score and cytokine profiles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome parameter:

      compound score of standardized neuropsychological test

      Secondary parameters:

        -  olfactory function (Sniffin Sticks)

        -  total neuropathy score (TNS), reduced version (clinical examination, neurography of
           sural and peroneal nerve)

        -  cytokine profiling from serum samples (ELISA)

        -  quality of life (questionnaire)

        -  depression screening (questionnaire)

        -  symptoms of polyneuropathy (questionnaire)

        -  symptoms of cognitive impairment (everyday memory test questionnaire)

      Assessment time points:

        -  baseline (after surgical tumor resection and before chemotherapy)

        -  follow up 1 (3 weeks after last chemotherapy cycle or 21 weeks (control patients))

        -  follow up 2 (optional; 1 year after chemotherapy completion)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline compound score of standardized neuropsychological test</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>standardized neuropsychological test covering verbal memory, visual-spatial memory, short term/ working memory, executive functions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline olfactory function</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>standardized test battery (Sniffin Sticks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline total neuropathy score (TNSr)</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>reduced version includes clinical examination and neurography of sural and peroneal nerve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline cytokine profiling (serum sample)</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>ELISA of serum samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline quality of life questionnaire</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>EORTC-QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline depression screening questionnaire</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>DESC-I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline symptoms of polyneuropathy questionnaire</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>EORTC-QLQ-C30+CIPN20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline symptoms of cognitive decline (questionnaire)</measure>
    <time_frame>3 weeks after last chemotherapy cycle (21 weeks)</time_frame>
    <description>everyday memory test</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cognition Disorders</condition>
  <condition>Polyneuropathies</condition>
  <arm_group>
    <arm_group_label>Chemotherapy Ovarian</arm_group_label>
    <description>patients with ovarian cancer and paclitaxel/ carboplatin combination chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Ovarian</arm_group_label>
    <description>patients with benign gynecological tumors after surgical tumor resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy Breast</arm_group_label>
    <description>patients with breast cancer and epirubicin/cyclophosphamide/paclitaxel combination chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Breast</arm_group_label>
    <description>patients with breast cancer and radiation and/or antihormonal treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>ovarian: carboplatin + paclitaxel breast: epirubicin + cyclophosphamide + paclitaxel</description>
    <arm_group_label>Chemotherapy Ovarian</arm_group_label>
    <arm_group_label>Chemotherapy Breast</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic, department of gynecology
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age

          -  written informed consent

          -  Karnofsky index &gt;70% / ECOG &lt;1

          -  at least 8 years of education

        Exclusion Criteria:

          -  post surgical delirium

          -  major depression

          -  alcohol or drug abuse

          -  anemia &lt; 8 g/dl

          -  mild cognitive impairment or dementia

          -  previous chemotherapy treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Huehnchen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra Huehnchen, Dr.</last_name>
    <phone>0049-30-450-560137</phone>
    <email>petra.huehnchen@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wolfgang Boehmerle, Dr., M.Sc.</last_name>
    <phone>0049-30-450-560137</phone>
    <email>wolfgang.boehmerle@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Petra Huehnchen</investigator_full_name>
    <investigator_title>resident and postdoctoral fellow</investigator_title>
  </responsible_party>
  <keyword>cognition</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>polyneuropathy</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>cancer</keyword>
  <keyword>chemobrain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

